Atea Pharmaceuticals (AVIR)

• Market cap: $252M
• 1 day: 0.00%
• 5 days: 2.43%
• 1 month: -1.34%
• 3 months: -1.34%
• 6 months: -10.06%
• Year to date: -13.74%
• 1 year: -20.27%
• 5 years: -90.28%
• 10 years: -90.28%
• Sector: Healthcare
• Industry: Biotechnology

About: Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Employees: 56

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

19% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 32

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

3% less capital invested

Capital invested by funds: $194M [Q3] → $188M (-$5.7M) [Q4]

2.03% less ownership

Funds ownership: 68.59% [Q3] → 66.57% (-2.03%) [Q4]

3% less funds holding

Funds holding: 107 [Q3] → 104 (-3) [Q4]

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

55% less call options, than puts

Call options by funds: $115K | Put options by funds: $255K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $6 103% upside
• Avg. target: $6 103% upside
• High target: $6 103% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

Morgan Stanley Matthew Harrison 43% 1-year accuracy 10 / 23 met price target

103% upside $6

Equal-Weight Maintained

11 Apr 2025